Purple Biotech (PPBT) Assets Average (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Assets Average of $16.0 million for Q1 2026, down 55.96% year-over-year from $36.3 million in Q1 2025, and down 43.52% quarter-over-quarter from $28.3 million in Q4 2025.
Purple Biotech (PPBT) Assets Average (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Assets Average for 13 consecutive years, with $16.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 55.96% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 55.96% YoY), while the FY2025 annual figure was $27.3 million, down 32.86% from the prior year.
- Assets Average fell to $16.0 million in Q1 2026 per PPBT's latest filing, from $28.3 million in the prior quarter.
- Across five years, Assets Average topped out at $68.2 million in Q1 2022 and bottomed at $16.0 million in Q1 2026.
- Historically, Assets Average has averaged $44.0 million across 5 years, with a median of $42.1 million in 2024.
- Annual changes were most pronounced in 2025 — Assets Average rose 3.19% — and 2026, when it tumbled 55.96%.
- Purple Biotech's Assets Average stood at $56.6 million in 2022, then dropped by 20.85% to $44.8 million in 2023, then retreated by 19.46% to $36.1 million in 2024, then declined by 21.5% to $28.3 million in 2025, then sank by 43.52% to $16.0 million in 2026.
- Business Quant data shows PPBT's Assets Average at $16.0 million in Q1 2026, $28.3 million in Q4 2025, and $36.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | 14.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.99 Mn |
| Dec 31, 2025 | 28.32 Mn |
| Sep 30, 2025 | 36.72 Mn |
| Jun 30, 2025 | 34.99 Mn |
| Mar 31, 2025 | 36.32 Mn |
| Dec 31, 2024 | 36.07 Mn |
| Sep 30, 2024 | 35.59 Mn |
| Jun 30, 2024 | 37.96 Mn |
| Mar 31, 2024 | 42.08 Mn |
| Dec 31, 2023 | 44.79 Mn |
| Sep 30, 2023 | 46.64 Mn |
| Jun 30, 2023 | 50.54 Mn |
| Mar 31, 2023 | 53.85 Mn |
| Dec 31, 2022 | 56.58 Mn |
| Sep 30, 2022 | 60.14 Mn |
| Jun 30, 2022 | 64.02 Mn |
| Mar 31, 2022 | 68.25 Mn |
| Dec 31, 2021 | 71.91 Mn |
| Sep 30, 2021 | 75.06 Mn |
| Jun 30, 2021 | 79.22 Mn |